Huajun Zhang

Journal of Hematology & Oncology · with Chen · 2022

A researcher in the Science corpus: 1 paper; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Papers from Huajun Zhang's perspective

Ordered by how strongly the researchers Huajun Zhang trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. (Journal of Clinical Investigation)
  2. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma (Modern Pathology)
  3. Structural and biochemical basis of apoptotic activation by Smac/DIABLO (Nature)
  4. A randomised phase III trial of carboplatin compared with docetaxel in BRCA1/2 mutated and pre-specified triple negative breast cancer “BRCAness” subgroups: the TNT Trial (Nature Medicine)
  5. The clonal and mutational evolution spectrum of primary triple-negative breast cancers (Nature)
  6. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. (The Lancet Oncology)
  7. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-negative Breast Cancer (Clinical Cancer Research)
  8. Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer (Clinical Cancer Research)
  9. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. (New England Journal of Medicine)
  10. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression (Clinical Cancer Research)

Their papers